NC
IRWD icon

NinePointTwo Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

NinePointTwo Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$297K Hold
26,046
– – 0.12% 127
2023
Q3 		$250K Buy
+26,046
New +$255K 0.1% 120
2023
Q1 		– Sell
-16,024
Closed -$198K – 281
2022
Q4 		$198K Buy
+16,024
New +$182K 0.08% 122

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

NinePointTwo Capital's IRWD Position: Q4 2023 in Review

NinePointTwo Capital held its Ironwood Pharmaceuticals (IRWD) position steady in Q4 2023 at 26,046 shares worth $297K. The position accounts for 0.12% of the portfolio, ranked #127.

NinePointTwo Capital first reported a position in IRWD in Q4 2022 and has held it in 3 quarters since. 251 funds tracked by Wall St. Rank hold IRWD as of Q4 2023.

  • NinePointTwo Capital held 26,046 shares of Ironwood Pharmaceuticals worth $297K as of Q4 2023.
  • NinePointTwo Capital left its Ironwood Pharmaceuticals share count unchanged in Q4 2023.
  • Ironwood Pharmaceuticals made up 0.12% of NinePointTwo Capital's portfolio in Q4 2023, its #127 holding.
  • NinePointTwo Capital first reported a position in Ironwood Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • 251 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.